Core One Labs is a biotech company focused on bringing psychedelic medicine to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Under the guidance of world-leading microbiologist Executive Chairman Dr. Bob Hancock, Core One is developing new ways for producing psilocybin at a fraction of the price of the current market. Estimated market price is $7,000 to $10,000 USD per gram for synthetic psilocybin used in clinical trials. By using Core One's biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively for $10s to $100s of dollars.
Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.
An online survey of 430 investors who use online broker platforms found that half of respondents between 25 and 34 years old plan to spend 50% of their stimulus payments on stocks.
Meanwhile, 18- to 24-year-old retail investors involved in the survey planned to use 40% of any stimulus checks on stocks.
And 35- to 54-year-old retail investors surveyed planned to use 37% of their checks on stock market investment.